This is Allison’s personal multiple myeloma story, and others may be different. Allison is a paid spokesperson for GSK.

The research team, led by Professors Kwong Yok-lam (front right) and Eric Tse Wai-choi (front left), successfully utilises ...

During a live event, Patrick Moore, MD, discussed the superior efficacy with ide-cel vs standard care in relapsed/refractory ...

Ajai Chari, MD, stresses the importance of making bispecific therapies more accessible at the community level to improve outcomes in multiple myeloma.

The following is a summary of “Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma ...

Researchers proposed changing the recommendations for universal driving restrictions after CAR T-cell infusion.

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

Among other functions, the NK cells (natural killers, a type of lymphocyte forming part of the immune system) have the capacity to detect and eliminate cancer cells. But in some cases they cannot ...

While we've known that a healthy diet reduces the overall chance of getting cancer, there's now evidence that one eating plan ...

The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.

Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow (the soft, inner parts of certain bones where new blood cells are made). They are an important part of ...